Home/Filings/4/0001181431-04-023343
4//SEC Filing

BARRIER THERAPEUTICS INC 4

Accession 0001181431-04-023343

CIK 0001173657operating

Filed

Apr 29, 8:00 PM ET

Accepted

Apr 30, 2:52 PM ET

Size

30.0 KB

Accession

0001181431-04-023343

Insider Transaction Report

Form 4
Period: 2004-04-28
Transactions
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
DENINO MARK J
10% Owner
Transactions
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
Transactions
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
Transactions
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
Transactions
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
Transactions
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
Transactions
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
Transactions
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
Transactions
  • Conversion

    Series C Preferred Stock

    2004-04-2810,2350 total
    Common Stock (5,117 underlying)
  • Conversion

    Common Stock

    2004-04-28+1,934,2171,934,217 total
  • Conversion

    Common Stock

    2004-04-28+33,45433,454 total
  • Conversion

    Series B Preferred Stock

    2004-04-2856,6740 total
    Common Stock (28,337 underlying)
  • Conversion

    Series C Preferred Stock

    2004-04-28591,7750 total
    Common Stock (295,887 underlying)
  • Conversion

    Series B Preferred Stock

    2004-04-283,276,6600 total
    Common Stock (1,638,330 underlying)
Footnotes (3)
  • [F1]All of the outstanding shares of the Issuer's Series B and Series C Convertible Preferred Stock converted automatically on a 2-for-1 basis into Common Stock of the Issuer just prior to the Issuer's initial public offering.
  • [F2]See Exhibit 99.1. Shares are held by TL Ventures V L.P. ("TL V"). TL Ventures V Management L.P. ("TLV Mgmt L.P"), the general partner of TL V, TL Ventures V LLC ("TLV LLC"), the general partner of TLV Mgmt L.P., and Robert E. Keith, Jr., Gary J. Anderson, Mark J. DeNino, Christopher Moller Ph.D, Anthony Craig, Christopher J. Davis and Robert N. Verratti, the members of the executive board of TLV LLC, together with Dr. Ostro, may be deemed to share voting and dispositive power over the shares held by TL V. Such persons and entities disclaim beneficial ownership of shares held by TL V except to the extent of any pecuniary interest therein.
  • [F3]See Exhibit 99.1. Shares are held by TL Ventures V Interfund L.P. ("TL V Interfund"). TL V LLC, the general partner of TL V Interfund, and Robert E. Keith, Jr., Gary J. Anderson, Mark J. DeNino, Christopher Moller Ph.D, Anthony Craig, Christopher J. Davis and Robert N. Verratti, the members of the executive board of TL V LLC, together with Dr. Ostro, may be deemed to share voting and dispositive power over the shares held by TL V Interfund. Such persons and entities disclaim beneficial ownership of shares held by TL V Interfund except to the extent of any pecuniary interest therein.

Issuer

BARRIER THERAPEUTICS INC

CIK 0001173657

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001173657

Filing Metadata

Form type
4
Filed
Apr 29, 8:00 PM ET
Accepted
Apr 30, 2:52 PM ET
Size
30.0 KB